Division of Health Sciences, Warwick Medical School, Gibbet Hill Campus, University of Warwick, Coventry, CV4 7AL, UK.
Warwick Clinical Trials Unit, University of Warwick, Coventry, UK.
Knee Surg Sports Traumatol Arthrosc. 2019 Jun;27(6):1825-1839. doi: 10.1007/s00167-019-05504-4. Epub 2019 Apr 13.
To assess the clinical effectiveness and cost-effectiveness of meniscal allograft transplantation (MAT) after meniscal injury and subsequent meniscectomy.
Systematic review of clinical effectiveness and cost-effectiveness analysis.
There is considerable evidence from observational studies, of improvement in symptoms after meniscal allograft transplantation, but we found only one small pilot trial with a randomised comparison with a control group that received non-surgical care. MAT has not yet been proven to be chondroprotective. Cost-effectiveness analysis is not possible due to a lack of data on the effectiveness of MAT compared to non-surgical care.
The benefits of MAT include symptomatic relief and restoration of at least some previous activities, which will be reflected in utility values and hence in quality-adjusted life years, and in the longer term, prevention or delay of osteoarthritis, and avoidance or postponement of some knee replacements, with resulting savings. It is likely to be cost-effective, but this cannot be proven on the basis of present evidence.
IV.
评估半月板移植（MAT）治疗半月板损伤和半月板切除后继发疾病的临床疗效和成本效益。
对临床疗效和成本效益分析进行系统评价。
大量观察性研究证据表明，半月板移植后症状有所改善，但我们只发现了一项小型试点试验，该试验对接受非手术治疗的对照组进行了随机比较。MAT 尚未被证明具有软骨保护作用。由于缺乏 MAT 与非手术治疗相比的有效性数据，因此无法进行成本效益分析。
MAT 的益处包括缓解症状和恢复至少部分先前的活动，这将反映在效用值，从而反映在质量调整生命年上，从长远来看，预防或延迟骨关节炎，避免或推迟一些膝关节置换，从而节省成本。MAT 很可能具有成本效益，但根据目前的证据尚无法证明这一点。
IV 级。
